Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: Diethylstilbestrol (DES)-polyacetals as prostate cancer treatment
- 1 April 2012
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 159 (2) , 290-301
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Polymer–drug conjugates as nano-sized medicinesCurrent Opinion in Biotechnology, 2011
- Curcumin polymers as anticancer conjugatesBiomaterials, 2010
- The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cellsThe Prostate, 2010
- Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicinesAdvanced Drug Delivery Reviews, 2009
- The uptake of N-(2-hydroxypropyl)-methacrylamide based homo, random and block copolymers by human multi-drug resistant breast adenocarcinoma cellsBiomaterials, 2009
- Live cell imaging for target and drug discoveryDrug News & Perspectives, 2009
- Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?Journal of Controlled Release, 2008
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006
- A Phenomenological Approach to Separating the Effects of Obstruction and Binding for the Diffusion of Small Molecules in Polymer SolutionsMacromolecules, 2003
- Differential Effects of Diethylstilbestrol and 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Thymocyte Differentiation, Proliferation, and Apoptosis in bcl-2 Transgenic Mouse Fetal Thymus Organ CultureToxicology and Applied Pharmacology, 2000